Benzinga | Feb 23, 2021 04:10PM EST

Myriad Genetics Q2 Adj. EPS $(0.12), Inline, Sales $154.60M Beat $150.39M Estimate

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 152.17 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $154.60 million which beat the analyst consensus estimate of $150.39 million by 2.80 percent. This is a 20.76 percent decrease over sales of $195.10 million the same period last year.